As an additional control, we targeted HER2 signaling using the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib and assessed SorLA levels in the lapatinib‐sensitive HER2+ BT‐474 and SK‐BR‐3 breast cancer cells. This evidence concerns the gene EGFR and breast cancer.